Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.

Ncardia, iPSC technology leader, taps industry veteran to drive growth in cell therapy and drug discovery markets.

Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide.